{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:30:37Z","timestamp":1778221837620,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11912-022-01197-0","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T09:04:06Z","timestamp":1642755846000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach"],"prefix":"10.1007","volume":"24","author":[{"given":"Camilo","family":"Jimenez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"6","key":"1197_CR1","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","volume":"104","author":"S Hescot","year":"2019","unstructured":"Hescot S, Curras-Freixes M, Deutschbein T, et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European Network for the Study of Adrenal Tumors retrospective study. J Clin Endocrinol Metab. 2019;104(6):2367\u201374.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1197_CR2","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.beem.2019.101354","volume":"34","author":"S Jasim","year":"2020","unstructured":"Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101354.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"1197_CR3","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1002\/hed.26421","volume":"42","author":"FS Lozano","year":"2020","unstructured":"Lozano FS, Munoz A, de Las Heras JA, Gonzalez-Porras JR. Simple and complex carotid paragangliomas. Three decades of experience and literature review. Head Neck. 2020;42(12):3538\u201350.","journal-title":"Head Neck"},{"issue":"3","key":"1197_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","volume":"96","author":"M Ayala-Ramirez","year":"2011","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1530\/EJE-15-0456","volume":"173","author":"S Thosani","year":"2015","unstructured":"Thosani S, Ayala-Ramirez M, Roman-Gonzalez A, et al. Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. Eur J Endocrinol. 2015;173(3):377\u201387.","journal-title":"Eur J Endocrinol"},{"key":"1197_CR6","doi-asserted-by":"crossref","unstructured":"Y-Hassan S, Falhammar H. Cardiovascular manifestations and complications of pheochromocytomas and paragangliomas. J Clin Med.\u00a02020;9(8):2435.","DOI":"10.3390\/jcm9082435"},{"issue":"4","key":"1197_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","volume":"50","author":"L Fishbein","year":"2021","unstructured":"\u2022\u2022 Fishbein L, Del Rivero J, Else T, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma. Pancreas. 2021;50(4):469-493. (First consensus guidelines in North America on the treatment of metastatic pheochromocytomas and paragangliomas)","journal-title":"Pancreas"},{"issue":"4","key":"1197_CR8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1210\/jc.2012-4231","volume":"98","author":"M Ayala-Ramirez","year":"2013","unstructured":"Ayala-Ramirez M, Palmer JL, Hofmann MC, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98(4):1492\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"\u2022 Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg. 2018;268(1):172-178. ( The results of this study suggest substantial benefits derived from surgery of the primary tumor in the context of metastases.)","journal-title":"Ann Surg"},{"issue":"9","key":"1197_CR10","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1210\/jc.2017-00992","volume":"102","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, Iniguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296\u2013305.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1197_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK Lam","year":"2017","unstructured":"Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28(3):213\u201327.","journal-title":"Endocr Pathol"},{"issue":"4","key":"1197_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"Jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep. 2013;15(4):356\u201371.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1197_CR13","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98(10):4006\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1197_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MED.0000000000000330","volume":"24","author":"A Roman-Gonzalez","year":"2017","unstructured":"Roman-Gonzalez A, Jimenez C. Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. Curr Opin Endocrinol Diabetes Obes. 2017;24(3):174\u201383.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1197_CR15","unstructured":"\u2022 Amin MB, Edge SB, Greene FL, al. et. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. pages 919\u2013927.(TNM staging for pheochromocytomas and paragangliomas)"},{"key":"1197_CR16","doi-asserted-by":"crossref","unstructured":"\u2022\u2022.Pryma DA, Chin BB, Noto RB, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623\u2013630.( The results of this phase 2 clinical trial led to the FDA approval of high specific activity MIBG for the treatment of metastatic pheochromocytoma and paraganglioma. This is currently the first and only treatment approved for this disease in the USA.)","DOI":"10.2967\/jnumed.118.217463"},{"issue":"4","key":"1197_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.surg.2013.12.024","volume":"155","author":"E Bertani","year":"2014","unstructured":"Bertani E, Fazio N, Botteri E, et al. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. Surgery. 2014;155(4):607\u201314.","journal-title":"Surgery"},{"issue":"3","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171(3):R111-122.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1197_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12020-017-1515-y","volume":"59","author":"G Gravel","year":"2018","unstructured":"Gravel G, Leboulleux S, Tselikas L, et al. Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine. 2018;59(3):547\u201354.","journal-title":"Endocrine"},{"issue":"5","key":"1197_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81(5):642\u201351.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1197_CR21","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012;118(11):2804\u201312.","journal-title":"Cancer"},{"issue":"3 Pt 2","key":"1197_CR22","first-page":"I18","volume":"7","author":"HR Keiser","year":"1985","unstructured":"Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension. 1985;7(3 Pt 2):I18-24.","journal-title":"Hypertension"},{"issue":"2","key":"1197_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4(2):103\u201310.","journal-title":"Horm Cancer"},{"issue":"1","key":"1197_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1677\/ERC-08-0190","volume":"16","author":"J Guillemot","year":"2009","unstructured":"Guillemot J, Compagnon P, Cartier D, et al. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009;16(1):281\u201390.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1197_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","volume":"19","author":"P Jimenez","year":"2017","unstructured":"Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C. Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress. Curr Oncol Rep. 2017;19(12):83.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"1197_CR26","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711\u201320.","journal-title":"Int J Cancer"},{"key":"1197_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fendo.2020.00061","volume":"11","author":"A Tong","year":"2020","unstructured":"Tong A, Li M, Cui Y, Ma X, Wang H, Li Y. Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature. Front Endocrinol (Lausanne). 2020;11:61.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"14","key":"1197_CR28","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-17-3406","volume":"24","author":"Y Pang","year":"2018","unstructured":"Pang Y, Lu Y, Caisova V, et al. Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. Clin Cancer Res. 2018;24(14):3423\u201332.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1197_CR29","doi-asserted-by":"publisher","first-page":"L51","DOI":"10.1530\/ERC-17-0086","volume":"24","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Ben-Maimon S, Keefe S, et al. SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer. 2017;24(8):L51\u20135.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1197_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","volume":"46","author":"JA Carrasquillo","year":"2016","unstructured":"Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma. Semin Nucl Med. 2016;46(3):203\u201314.","journal-title":"Semin Nucl Med"},{"issue":"9","key":"1197_CR31","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab. 2017;102(9):3278\u201387.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1197_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12149-020-01541-z","volume":"35","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, Talole S, Basu S. (131)I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with (177)Lu-DOTATATE peptide receptor radionuclide therapy. Ann Nucl Med. 2021;35(1):92\u2013101.","journal-title":"Ann Nucl Med"},{"issue":"4","key":"1197_CR33","first-page":"334","volume":"52","author":"F Forrer","year":"2008","unstructured":"Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"1197_CR34","doi-asserted-by":"crossref","unstructured":"Kolasinska-Cwikla A, Peczkowska M, Cwikla JB, et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J Clin Med.\u00a02019;8(7):952.","DOI":"10.3390\/jcm8070952"},{"issue":"4","key":"1197_CR35","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","volume":"6","author":"S Severi","year":"2021","unstructured":"Severi S, Bongiovanni A, Ferrara M, et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open. 2021;6(4):100171.","journal-title":"ESMO Open"},{"issue":"1","key":"1197_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","volume":"181","author":"WT Zandee","year":"2019","unstructured":"Zandee WT, Feelders RA, Smit Duijzentkunst DA, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181(1):45\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1197_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/cbr.2009.0695","volume":"25","author":"JA Barrett","year":"2010","unstructured":"Barrett JA, Joyal JL, Hillier SM, et al. Comparison of high-specific-activity ultratrace 123\/131I-MIBG and carrier-added 123\/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm. 2010;25(3):299\u2013308.","journal-title":"Cancer Biother Radiopharm"},{"key":"1197_CR38","unstructured":"Azedra prescribing information. Progenics Pharmaceuticals Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209607s000lbl.pdf. Published 2018. Accessed June 26, 2021."},{"key":"1197_CR39","doi-asserted-by":"crossref","unstructured":"Giammarile F, Chiti A, Lassmann M, Brans B, Flux G, Eanm. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039\u20131047.","DOI":"10.1007\/s00259-008-0715-3"},{"issue":"11","key":"1197_CR40","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"\u2022 Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-1490. (European guidelines on the management of metastatic pheochromocytomas and paragangliomas.)","journal-title":"Ann Oncol"},{"issue":"3","key":"1197_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","volume":"49","author":"W Makis","year":"2015","unstructured":"Makis W, McCann K, McEwan AJ. The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols. Nucl Med Mol Imaging. 2015;49(3):223\u201330.","journal-title":"Nucl Med Mol Imaging"},{"issue":"11","key":"1197_CR42","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","volume":"27","author":"A Jha","year":"2021","unstructured":"Jha A, Taieb D, Carrasquillo JA, et al. High-specific-activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2021;27(11):2989\u201395.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1197_CR43","doi-asserted-by":"publisher","first-page":"R239","DOI":"10.1530\/ERC-20-0043","volume":"27","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, Fazeli S, Roman-Gonzalez A. Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2020;27(7):R239\u201354.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"1197_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019;120(12):1113\u20139.","journal-title":"Br J Cancer"},{"issue":"2","key":"1197_CR45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","volume":"57","author":"S Jasim","year":"2017","unstructured":"Jasim S, Suman VJ, Jimenez C, et al. Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017;57(2):220\u20135.","journal-title":"Endocrine"},{"issue":"8","key":"1197_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491\u2013501.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1197_CR47","doi-asserted-by":"publisher","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","volume":"98","author":"S Thosani","year":"2013","unstructured":"Thosani S, Ayala-Ramirez M, Palmer L, et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013;98(11):E1813-1819.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1197_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","volume":"7","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7(3):213\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1197_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2018.00277","volume":"9","author":"C Jimenez","year":"2018","unstructured":"Jimenez C. Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer. Front Endocrinol (Lausanne). 2018;9:277.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"1197_CR50","doi-asserted-by":"publisher","first-page":"e1358332","DOI":"10.1080\/2162402X.2017.1358332","volume":"6","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Black JR, Trousil S, et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology. 2017;6(11):e1358332.","journal-title":"Oncoimmunology"},{"key":"1197_CR51","doi-asserted-by":"crossref","unstructured":"Jimenez C, Subbiah V, Stephen B, et al. Phase II clinical trial\u00a0of pembrolizumab in patients with progressive metastatic\u00a0pheochromocytomas and paragangliomas. Cancers (Basel).\u00a02020;12(8):2307.","DOI":"10.3390\/cancers12082307"},{"key":"1197_CR52","doi-asserted-by":"publisher","first-page":"594264","DOI":"10.3389\/fendo.2020.594264","volume":"11","author":"MP Economides","year":"2020","unstructured":"Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A durable response with the combination of nivolumab and cabozantinib in a patient with metastatic paraganglioma: a case report and review of the current literature. Front Endocrinol (Lausanne). 2020;11:594264.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1197_CR53","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/MED.0000000000000544","volume":"27","author":"C Jimenez","year":"2020","unstructured":"Jimenez C, Nunez R, Wendt R. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. Curr Opin Endocrinol Diabetes Obes. 2020;27(3):162\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1197_CR54","doi-asserted-by":"crossref","unstructured":"Jimenez C, Erwin W, Chasen B. Targeted radionuclide therapy\u00a0for patients with metastatic pheochromocytoma and paraganglioma:\u00a0from low-specific-activity to high-specific-activity\u00a0iodine-131 metaiodobenzylguanidine. Cancers (Basel).\u00a02019;11(7):1018.","DOI":"10.3390\/cancers11071018"},{"issue":"5","key":"1197_CR55","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27(5):802\u20135.","journal-title":"Nat Med"},{"issue":"5","key":"1197_CR56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/13543784.2021.1925248","volume":"30","author":"E Hasanov","year":"2021","unstructured":"Hasanov E, Jonasch E. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opin Investig Drugs. 2021;30(5):495\u2013504.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"1197_CR57","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/PAS.0000000000001768","volume":"45","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma J, Jimenez C, Zhang M. Pheochromocytoma: a clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol. 2021;45(9):1155\u201365.","journal-title":"Am J Surg Pathol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01197-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T08:21:53Z","timestamp":1666513313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01197-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01197-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"21 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Camilo Jimenez has received research support from Lantheus Pharmaceuticals, Exelixis, Merck Sharp and Dohme, and Pfizer; Camilo Jimenez is consultant for Lantheus, Merck Sharp and Dohme, Pfizer, and HRA Pharma.Matthew T. Campbell is consultant for AstraZeneca, Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, AXDev, and Pfizer. Matthew T. Campbell has received research support from Apricity Health, Aravive, AstraZeneca, EMD Serono, Exelixis, Janssen, and Pfizer; non-CME education: Bristol Myers Squibb, Merck, Roche, and Pfizer.Yang Lu is consultant for General Electric, Inc.Jeena Varghese, Guofan Xu, and Paul Graham do not have conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}